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Abstract Aim The purpose of this study was to investi-
gate to what extent patients using prescription antiobesity
drugs (orlistat, sibutramine and rimonabant) used cardio-
vascular and antidiabetic drugs. An additional aim was to
investigate whether such co-medication differed according
to gender, age and amount of antiobesity drugs used.
Method Data were retrieved from the Norwegian Pre-
scription Database (NorPD). All patients who had an
antiobesity drug (ATC code A08A) dispensed from a
Norwegian pharmacy between January 2004 and December
2007 were included in the study. Results During the 4-year
study period 83,717 patients had antiobesity drugs dis-
pensed. One in three patients using antiobesity drugs had at
least on one occasion used a cardiovascular and/or an
antidiabetic drug concomitantly. A signiﬁcantly higher
percentage of men used antihypertensives (40.4 vs.
27.2%, P\0.0005), lipid modifying agents (24.4 vs. 11.9%,
P\0.0005) and drugs used in diabetes (12.7 vs. 6.4%,
P\0.0005) concomitantly with antiobesity drugs when
compared to women. The percentage of patients who had
concomitant drug use increased markedly with age. One in
four patients had antiobesity drugs dispensed only once
during the period 2004–2007. Conclusion Use of
cardiovascular and antidiabetic drugs among patients using
antiobesity drugs was extensive, especially among men and
elderly patients. Overall, there was a high degree of poly-
pharmacy among users of antiobesity drugs. Also, many
patients dispensed antiobesity drugs in amounts that indi-
cated use less than the recommended daily dose, and many
dispensed antiobesity drugs only once. When prescribing
antiobesity drugs to patients the potential beneﬁts of anti-
obesity drugs should be considered in relation to the
patients other chronic diseases and to the total complexity
of the patients drug regimen.
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Impact of ﬁndings on practice
• One out of every three patients using antiobesity drugs,
also use cardiovascular and/or an antidiabetic
medication.
• Users of antiobesity drugs in Norway are most com-
monly women, and between 50 and 59 years old.
• In Norway, polypharmacy is extensive among patient
using antiobesity drugs with an average of seven
prescribed drugs per patient per year.
Introduction
WHO estimated in 2005 that approximately 1.6 billion
adults were overweight and at least 400 million adults were
obese [1]. Overweight and obesity pose a major risk for
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2-diabetes, cardiovascular diseases, hypertension and
stroke [2, 3]. The health consequences range from
increased risk of premature death, to serious chronic con-
ditions that reduce the overall quality of life [2]. The
metabolic and vascular beneﬁts of even modest reductions
in weight have been well described [3].
The literature on drug use among overweight and obese
patients is strikingly sparse. Two studies have demon-
strated that a higher percentage of obese patients use pre-
scription drugs compared to patients of normal weight
[4, 5]. In a study with 2,300 patients in the UK, a higher
percentage of obese patients used drugs affecting the car-
diovascular system (36.1 vs. 20.1%) and the endocrine
system (26.0 vs. 17.9%) when compared to patients of
normal weight [4]. The prescribing volume (number of
deﬁned daily doses, DDD) was also higher among obese
patients [4]. In a Dutch study from 2006 they found that a
higher percentage of women compared to men were pre-
scribed cardiovascular drugs (ATC-category C) (28.8 vs.
25.2% among overweight patients and 37.8 vs. 32.1%
among obese patients) [5].
An American study has shown that only 1.6%
drug-eligible obese patients trying to lose weight used
antiobesity drugs [6]. Having concurrent dyslipidaemia
was signiﬁcantly associated with a decreased likelihood of
receiving a prescription antiobesity drug, and having
hypertension was not associated with having an antiobesity
prescription either [7].
There are two drugs approved for the treatment of
obesity in Norway: orlistat (Xenical
 , Roche) and sibutr-
amine (Reductil
 , Abbott). These drugs are indicated as
adjunctive therapy within a weight management program
for obese patients (BMI C 30) or overweight patients
(BMI C 28/27) if other obesity-related risk factors such as
type 2-diabetes or dyslipidaemia are present [8, 9]. When
compared to placebo, orlistat reduces weight by 2.9 kg
(95% CI 2.5–3.2 kg) and sibutramine by 4.2 kg
(3.6–4.7 kg) [10]. Weight loss with orlistat is also associ-
ated with a reduced incidence of diabetes and improved
concentrations of total cholesterol and low density lipo-
protein cholesterol (LDL-cholesterol), lowered blood
pressure and improved glycemic control in patients with
diabetes. Treatment with orlistat increases rates of gastro-
intestinal side effects and slightly lowers concentrations of
high density lipoprotein cholesterol (HDL-cholesterol).
Weight loss with sibutramine is associated with increased
concentrations of HDL-cholesterol and lowered triglycer-
ides-levels, but can lead to raised blood pressure and pulse
rate [10]. Sibutramine has temporarily been removed from
the European market due to an increased risk of serious,
non-fatal cardiovascular events, such as stroke or heart
attack [11].
In 2006 rimonabant (Acomplia
 , Sanoﬁ-Aventis) was
approved for the treatment of obesity in Norway. Com-
pared to placebo, rimonabant reduces weight by 4.7 kg
(4.1–5.3 kg) and improves concentrations of HDL-choles-
terol and triglycerides, blood pressure and glycemic control
in patients with diabetes but increases the risk of mood
disorders [10, 12]. However, the drug was suspended in
Europe in October 2008 as a group of endocrinologists,
cardiologists and psychiatrists concluded that the beneﬁts
of the drug no longer outweighed its risks [13, 14]. The risk
of psychiatric side effects was approximately twice as high
in patients taking rimonabant compared to patients taking
placebo.
Few pharmacoepidemiological studies on the charac-
teristics of patients using antiobesity drugs have been
conducted so far. A population-based study in Denmark
showed that over 50% of the patients using antiobesity
drugs were at the same time treated for type 2-diabetes,
hypertension or dyslipidaemia [15]. However, ‘at the same
time’ was in this study deﬁned as having antiobesity and
antidiabetic drugs, antihypertensives or lipid modifying
agents dispensed between 1994 and 2007 regardless of
whether there was an overlap with treatment with anti-
obesity drugs.
A population-based study from the Netherland found
that diabetes mellitus and hypertension was twice as pre-
valent among patients starting to use antiobesity drugs
when compared to overweight patients not being pre-
scribed antiobesity drugs [16]. In addition, they found that
antiobesity drugs were used for a relatively short period of
time, and the majority of the patients received only a single
prescription in the year following the index date.
Despite our limited knowledge on how antiobesity drugs
are being used, these drugs are currently widely used. Drug
sales in the global antiobesity market approached US $2
billion in 2008 [17].
The aim of the present study was to investigate to what
extent patients using prescription antiobesity drugs (orli-
stat, sibutramine and rimonabant) in Norway used cardio-
vascular and antidiabetic drugs. An additional aim was to
investigate whether such co-medication differed according
to gender, age and amount of antiobesity drugs used. By
investigating these issues we hope to achieve an increase in




Data were retrieved from the Norwegian Prescription
Database (NorPD). NorPD covers the entire Norwegian
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123population (4.7 million inhabitants) [18]. Since the 1st of
January 2004, the Norwegian Institute of Public Health has
received monthly data on prescriptions from all Norwegian
pharmacies [18]. During 2004–2007 more than 4.2 million
individuals have been recorded in NorPD with at least one
prescription drug dispensed from a pharmacy. NorPD
contains information about all drugs prescribed (reim-
bursed or not) and dispensed at pharmacies to individual
patients in primary care. Drugs sold over-the-counter
(OTC) are not recorded. Some of the data collected are the
patients’ unique identiﬁcation numbers (encrypted), gender
and age, the prescribers’ unique identiﬁcation number
(encrypted), the date of dispensing, drug information (e.g.,
package size, number of packages and ATC code) and
number of DDD dispensed [18].
Patients
All patients who had an antiobesity drug (ATC code
A08A) dispensed between the 1st of January 2004 and the
31st of December 2007 were included in the study. During
the study period this included 3 drugs: orlistat (ATC code
A08A B01), sibutramine (ATC A08A A10) and rimona-
bant (ATC A08AX01). Information on all other prescrip-
tion drugs these patients were dispensed during the same
period was also retrieved. Cardiovascular and antidiabetic
drugs were deﬁned according to the Anatomical Thera-
peutic Chemical (ATC) classiﬁcation system and included
the following subgroups: antihypertensives (ATC groups
C02, C03, C07, C08 and C09), lipid modifying agents
(ATC group C10) and drugs used in diabetes (ATC group
A10). ATC/DDD version from January 2008 was used in
this study [19].
Data analysis
One year prevalence and prevalence for the 4-year period
(per 1,000 inhabitants) of antiobesity drug use were cal-
culated. Prevalence was stratiﬁed by gender and age group
(\10, 10–19, 20–29 years etc. up to[90 years). The gen-
der and age distribution was compared to the distribution of
all patients included in NorPD in 2007 (n = 3,215,584).
We also calculated the number of times the patients had
antiobesity drugs dispensed and the number of DDD they
dispensed during their treatment. DDD were employed as
units of measurements as prescribed daily doses were not
available from the NorPD. The period of treatment was
deﬁned as the period between the ﬁrst date the patient had
antiobesity drugs dispensed and the last date the patient had
any antiobesity drugs left according to dispensed DDD’s.
Daily users were deﬁned as those using on average 1 DDD
per day (±20%) during their period of treatment. Low and
high consumers were deﬁned as patients using on average
less than 0.5 DDD per day and more than 1.5 DDD per day,
respectively. Season variation was calculated as the aver-
age number of prescriptions dispensed each month during
the study period.
Co-medication with cardiovascular and antidiabetic
drugs was deﬁned in two different ways; ‘concomitant’ if
treatment with the cardiovascular/antidiabetic drugs and
antiobesity drugs were overlapping, and ‘concurrent’ if the
different drugs were dispensed during the same year. A
more detailed description on the deﬁnition of concomitant
and concurrent drug use is given by Tobi et al. [20]. The
proportion of patients in the study population who had
concomitant/concurrent drug use was compared with the
entire NorPD population with respect to use of cardiovas-
cular drugs and drugs used in diabetes.
Student’s t test was used for comparing means and v
2 test
was used to investigate factors associated with co-medica-
tion among the patients. Large-sample signiﬁcance tests for
comparing two proportions were used to compare the extent
of co-medication between different groups. Statistical tests
were considered signiﬁcant when P\0.05 (two-tailed). All
statistical analyses were performed with the Statistical
PackageforSocialSciencesSPSSforWindowsversion16.0
(SPSS, Chicago, IL, USA).
Results
The characteristics of patients using antiobesity drugs
During the 4-year period (2004–2007) there were 83,717
patients who had antiobesity drugs dispensed in Norway;
approximately35,600patientseachyear(7.8usersper1,000
inhabitants).Orlistat wasdispensed to57.8%ofthe patients,
sibutramine to 51.2% and rimonabant to 6.9%. Overall
78.5% of the patients were women. The median age at the
ﬁrst dispensed antiobesity drug was 44 years for the total
study population. Women were signiﬁcantly younger than
men (43 years for women and 46 years for men) when ﬁrst
dispensed an antiobesity drug (P\0.001). The prevalence
was highest among 50 to 59-year-olds with approximately
13 users per 1,000 inhabitants per day per year.
The patients had antiobesity drugs dispensed on average
3.5 times per year, and 5.9 times during the 4-year period.
A total of 25.0% of the patients had antiobesity drugs
dispensed only once. Among patients who had orlistat and
rimonabant dispensed, 51.4 and 60.5%, respectively, had
the drugs dispensed once or twice. Among the patients who
had antiobesity drugs dispensed more than once, 31.1%
were deﬁned as ‘daily users’ during the time they were on
antiobesity drug therapy, 35.7% were deﬁned low con-
sumers and 2.4% were high consumers. High consumers
were most frequently men (3.6 vs. 2.1%, P\0.001). Age
754 Pharm World Sci (2010) 32:752–758
123did not have a signiﬁcant impact on the consumption of
antiobesity drugs.
There was a marked season variation in use of the three
antiobesity drugs with the highest dispensing rate in June
(in average a total of 12,058 antiobesity prescriptions per
year) and lowest in February (in average 9,146 per year).
The patients had prescriptions dispensed for an average
of seven different drugs (different ATC 5th level codes,
range 1–64 drugs) prescribed by in average three different
physicians per year. The range of prescribing physicians
was 1–57. Women had slightly, but signiﬁcantly more
drugs prescribed (4.5 vs. 4.0 drugs, P\0.001) and from
more prescribers (in average 2.8 vs. 2.5, P\0.001) yearly.
The percentage of individuals who had drugs dispensed
that belong to the different ATC main groups was in 2007
over 40% higher among patients using antiobesity drugs
when compared to the general population in NorPD for
some ATC groups [ATC groups N—nervous system (53
vs. 37%), M—musculoskeletal system (47 vs. 28%), C—
cardiovascular system (39 vs. 27%), G—genital urinary
system and sex hormones (30 vs. 21%) and H—systemic
hormonal preparations excluding sex hormones and insulin
(18 vs. 11%)].
Use of cardiovascular and antidiabetic co-medication
There was considerable co-medication among the patients
who had antiobesity drugs dispensed during 2004–2007
(Table 1). A higher percentage of men had concomitant
use of antiobesity drugs and antihypertensives (40.4 vs.
27.2%, P\0.0005), lipid modifying drugs (24.4 vs. 11.9%,
P\0.0005) and drug used in diabetes (12.7 vs. 6.4%,
P\0.0005) when compared to women. The percentage
that had concomitant drug use increased markedly with age.
Patients who had antiobesity drugs dispensed only once
used other prescription drugs concomitantly less frequently
than patients who had the drugs dispensed more than once.
There were small, but signiﬁcant differences in the extent of
concomitant drug use between the different DDD/day-
groups (Table 1).
A signiﬁcantly higher percentage of the study popula-
tion had cardiovascular and antidiabetic drugs dispensed in
2007 when compared to the general NorPD population
(Table 2). The difference in percentages decreased with
age. The predominance of men was higher among patients
using antiobesity drugs when compared to the patients in
NorPD.














n % n % n % n % n %
Total study population 28,445 34.0 25,128 30.0 12,235 14.6 6,520 7.8 69,496 83.0
Gender
Men 8,212 45.7 7,261 40.4 4,386 24.4 2,286 12.7 14,270 79.4
Women 20,233 30.8 17,867 27.2 7,849 11.9 4,234 6.4 55,226 84.0
Age (years)
0–29 611 4.7 517 4.0 126 1.0 413 3.2 9,682 74.8
30–59 19,283 32.7 16,862 28.6 7,666 13.0 4,364 7.4 48,590 82.4
60–99 8,551 72.6 7,749 65.8 4,443 37.7 1,743 14.8 11,224 95.3
No. of prescriptions of antiobesity drugs
1 5,896 28.2 5,111 24.5 2,569 12.3 1,299 6.2 15,039 72.0
[1 22,549 35.9 20,017 31.9 9,666 15.4 5,221 8.3 54,457 86.7
Amount of antiobesity drugs dispensed (DDD/year)
\290 14,520 37.8 12,929 33.7 6,182 16.1 3,195 8.3 34,222 89.2
290–360 6,382 32.7 5,631 28.8 2,787 14.3 1,601 8.2 16,097 82.4
[360 1,647 33.6 1,457 29.7 697 14.2 425 8.7 4,138 84.3
a ATC group C
b ATC group C02, C03, C07, C08 and C09
c ATC group C10
d ATC group A10
e Any drug except antiobesity drugs
Pharm World Sci (2010) 32:752–758 755
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The use of antiobesity drugs differed both according to
gender and age. Difference in the occurrence of obesity
between men and women cannot alone explain the fact that
four out of ﬁve patients who had antiobesity drugs dis-
pensed were women. The percentage of obese individuals
is 20% among Norwegian inhabitants under the age of 60
irrespective of gender [21]. Factors more likely to explain
the higher frequency of female antiobesity drug users may
be that women tend to be more concerned about their
health and visit their GP more often than men [22, 23].
Women are also far more likely to seek and accept weight
management support from their family doctor [23].
Most patients were middle-aged (30–69 years). This can
be explained by the fact that the percentage of the Nor-
wegian population being obese is higher among adults than
among children and youths [21]. Younger patients do not
use drugs to the same extent as older patients either [18],
and consequently, their threshold for using drugs to lose
weight may be higher. Antiobesity drugs are also relatively
expensive (daily cost range from 1.75 to 3.10 €) and are not
reimbursed in Norway. This may also be an important
explanation for the limited use; only 1% of the patients in
NorPD used antiobesity drugs.
This study shows that approximately one out of three
patients who had antiobesity drugs dispensed also had
cardiovascular drugs or antidiabetic drugs dispensed,
indicating a high degree of metabolic and cardiovascular
co-morbidity. This is almost identical to a recently pub-
lished study from the Netherlands where 33% of patients
starting antiobesity drugs reported using cardiovascular
drugs [16]. Both these two studies demonstrate the mag-
nitude of cardiovascular diseases among these patients.
Patients with cardiovascular co-morbidity may especially
beneﬁt from reducing weight [3]. These patients may even
be prescribed antiobesity drugs as part of treatment for
their cardiovascular disease. We ﬁnd it therefore interesting
that men had a higher degree of co-medication with car-
diovascular and antidiabetic drugs compared to women,
and speculate that this can be due to a difference in the
frequency of underlying co-morbidity.
In addition to cardiovascular co-morbidity, our study
also demonstrates the magnitude of polypharmacy among
patients who had antiobesity drugs dispensed. Of impor-
tance, the patients in our study had in average seven dif-
ferent prescription drugs dispensed yearly. Several studies
have previously documented the many challenges related
to polypharmacy [24–28]. Adherence decreases with an
increasingly complex drug regimen [24, 27]. In addition,
the risk of drug interactions and adverse effects increases
with an increasing number of prescribed drugs [26]. A
recently published study on polypharmacy among diabetic
patients with cardiovascular co-morbidity showed that
many patients had poor adherence and little knowledge
about why the drugs were prescribed [28]. Our results
indicate that adherence or consumption of antiobesity
drugs is suboptimal as three out of ﬁve patients had a
dispensing pattern indicating use of doses less than the
deﬁned daily dose recommended. Also interestingly, many
patients had antiobesity drugs dispensed only once or twice
during 2004–2007. This applies especially for rimonabant
Table 2 Use of cardiovascular and antidiabetic drugs among patients who had antiobesity drugs dispensed (n = 36,772) and among the general
population (n = 3,215,584) in NorPD in 2007
Group Cardiovascular drugs
a Antihypertensives
b Lipid modifying agents
c Drugs used in diabetes
d
SP NorPD SP NorPD SP NorPD SP NorPD
Total use 36.7 27.5 33.4 22.5 17.0 12.4 9.4 4.1
Use according to gender
Men 48.7 29.2 44.7 23.8 28.3 14.7 15.1 5.0
Women 33.6 26.1 30.5 21.4 14.1 10.5 7.9 3.4
Use according to age (years)
0–29 4.6 2.0 4.0 0.7 0.8 0.2 3.9 0.8
30–59 32.1 20.5 28.5 15.0 13.0 8.3 8.1 3.4
60–99 73.7 65.7 69.3 57.6 41.9 32.0 17.6 8.8
Numbers given in percents
All differences in proportions (%) between SP and NorPD are statistic signiﬁcant (P\0.0005)
SP study population, NorPD Norwegian Prescription Database
a ATC group C
b ATC group C02, C03, C07, C08 and C09
c ATC group C10
d ATC group A10
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123and orlistat. Rimonabant was marketed in Norway in
September 2006, which may explain limited use of this
drug. The high prevalence of side effects associated with
the use of rimonabant, including depression, anxiety and
irritability, may also be an explanation. Gastrointestinal
side effects may lead to early termination of treatment with
orlistat. Therapy with orlistat should also be stopped after
12 weeks if the patient has been unable to lose at least 5%
of the body weight since the start of treatment [8]. Lack of
information from the prescribing physician can also lead to
short-term therapy [29]. The frequent side effects and the
relatively high drug prices may also explain why almost
one out of three patients who had antiobesity drugs dis-
pensed more than once were low consumers or had a dis-
continuous use of the medicine. In addition, lack of
effectiveness or perceived lack of effectiveness has been
shown to be an important cause of drug discontinuation
[24]. Antiobesity drugs have in average a weight loss of
3–5 kg which some patients may perceive as a marginal
effect [8, 9, 12].
Limitations
Data from NorPD does not provide information on vari-
ables like BMI and the indication for drug use. These
variables would have been valuable for estimating to what
extent the patients are treated in accordance with the
approved indications. The study is also based on drug
dispensing information. We do not know if the drugs were
actually taken by the patients and in which degree they
used the antiobesity drugs daily. Also the DDDs used in
our calculations were not necessarily the prescribed doses
or the doses actually taken by the patients. Our results
should be interpreted with these limitations in mind.
Conclusion
There was a high degree of polypharmacy among users of
antiobesity drugs; in average the patients had seven dif-
ferent drugs dispensed by three different physicians yearly.
More speciﬁcally, one out of three patients who had anti-
obesity drugs dispensed used cardiovascular drugs or
antidiabetic drugs. Such co-medication was especially
extensive among men and elderly patients. This indicates a
high degree of cardiovascular and metabolic co-morbidity
among these patients. Patients may not beneﬁt optimal of
the antiobesity drug as one out of three had doses dispensed
that indicate use of doses less than the recommended daily
dose. Also, as one out of four patients had antiobesity drugs
dispensed only once adverse effects, high drug cost and/or
perceived lack of effectiveness may be common. When
prescribing antiobesity drugs to patients the potential
beneﬁts of pharmacologically induced weight reduction
should be considered in relation to the patients other
chronic diseases and to the total complexity of the patients
drug regimen.
Acknowledgment We would like to thank ‘The Foundation for
Promotion of Norwegian Pharmacies’.
Funding This work was funded by ‘The Foundation for Promotion
of Norwegian Pharmacies’.
Conﬂicts of interest None.
Open Access This article is distributed under the terms of the
Creative Commons Attribution Noncommercial License which per-
mits any noncommercial use, distribution, and reproduction in any
medium, provided the original author(s) and source are credited.
References
1. WHO. Obesity and overweight. What are overweight and obes-
ity? http://www.who.int/mediacentre/factsheets/fs311/en/index.
html; 2006. Accessed 13 June 2010.
2. WHO. Obesity and overweight. http://www.who.int/hpr/NPH/
docs/gs_obesity.pdf; 2003. Accessed 13 June 2010.
3. Haslam D, Sattar N, Lean M. ABC of obesity. Obesity-time to
wake up. Br Med J. 2006;333:640–2.
4. Counterweight Project Team. The impact of obesity on drug
prescribing in primary care. Br J Gen Pract. 2005;55:743–9.
5. van Dijk L, Otters HB, Schuit AJ. Moderately overweight and
obese patients in general practice: a population based survey.
BMC Fam Pract. 2006;7:43.
6. Pokras SM, Klingman D, Annunziata K, Chapnick J, Tierce J.
Utilization and patient experience with obesity prescriptions in
the US. Pharmacoepidemiol Drug Saf. 2008;17(Suppl 1):S142
(abstract 324).
7. Pokras SM, Klingman D, Tierce JC. Factors associated with
prescription of obesity medications in the US. Pharmacoepi-
demiol Drug Saf. 2008;17(Suppl 1):S143 (abstract 326).
8. The Norwegian Medicines Agency. SPC—orlistat. http://www.
legemiddelverket.no/custom/Preparatsok/prepSearch____80333.
aspx?SearchID=0a6afb93-7531-4c58-b8b5-586062d5c4e8.A c c e s -
sed 13 June 2010.
9. The Norwegian Medicines Agency. SPC—reductil. http://www.
legemiddelverket.no/custom/Preparatsok/prepSearch____80333.
aspx?SearchID=a730bc6a-4b18-4e5b-9d81-a00da5aba98e.A c c e s -
sed 13 June 2010.
10. Rucker D, Padwal R, Li SK, Lau DC. Long term pharmaco-
therapy for obesity and overweight: updated meta-analysis. Br
Med J. 2007;335:1194–9.
11. EMEA. European Medicines Agency recommends suspension of
marketingauthorizationsforsibutramine.http://www.ema.europa.
eu/pdfs/human/referral/sibutramine/3940810en.pdf; 2010. Acces-
sed 13 July 2010.
12. EMEA. SPC—Acomplia. http://www.ema.europa.eu/humandocs/
PDFs/EPAR/acomplia/H-666-PI-da.pdf. Accessed 13 June 2010.
13. EMEA. Press release. The European Medicines Agency recom-
mends suspension of the marketing authorisation of Acomplia.
http://www.emea.europa.eu/humandocs/PDFs/EPAR/acomplia/
53777708en.pdf; 2008. Accessed 13 June 2010.
14. EMEA. Questions and answers on the recommendation to sus-
pend the marketing authorisation of Acomplia (rimonabant).
Pharm World Sci (2010) 32:752–758 757
123http://www.emea.europa.eu/humandocs/PDFs/EPAR/acomplia/
53715308en.pdf; 2008. Accessed 13 June 2010.
15. Lægemiddelstyrelsen. Brug af receptpligtige slankelægemidler
2003–2007 [Use of prescription antiobesity drugs]. http://www.
laegemiddelstyrelsen.dk/statistik/forbrugsanalyser/slankemidler/
slankemidler_notat2.asp; 2008. Accessed 13 June 2010 (in
Danish).
16. Willemen MJ, Mantel-Teeuwisse AK, Straus SM, Leufkens HG,
Egberts AC, Sturkenboom MC. Cardiovascular and psychiatric
risk proﬁle and patterns of use in patients starting anti-obesity
drugs. Pharmacoepidemiol Drug Saf. 2009;18:631–8.
17. Reuter. Learn about the anti-obesity treatments markets: analysis
& forecasts 2009–2024. http://www.reuters.com/article/pressRelease/
idUS139205?30-Mar-2009?BW20090330; 2009. Accessed 13
June 2010.
18. Rønning M, Berg CL, Furu K, Litleskare I, Sakshaug S, Strøm H.
The Norwegian Prescription Database 2004–2007. Oslo: The
Norwegian Institute of Public Health; 2008. ISBN:978-82-8082-
253-6.
19. WHO Collaborating Centre for Drug Statistics Methodology.
Guidelines for ATC classiﬁcation and DDD assignment 2008,
11th edn. Oslo: The Norwegian Institute of Public Health; 2007.
ISBN:978-82-8082-369-4.
20. Tobi H, Faber A, van den Berg PB, Drane JW, den Berg LT.
Studying co-medication patterns: the impact of deﬁnitions.
Pharmacoepidemiol Drug Saf. 2007;16:405–11.
21. Ulset E, Undheim R, Malterud K. Has the obesity epidemic
reached Norway? Tidsskr Nor Lægeforen. 2007;127:34–7 (in
Norwegian).
22. Ministry of Health and Care Services. NOU 1999: 13. Kvinners
helse i Norge. Kapittel 1.9: Kjønnsperspektiv pa ˚ helsetjenestetilbud
og –forbruk [Womens health in Norway. Chapter 1.9: The gender
perspective on health services and health services consumption] (in
Norwegian).
23. Counterweight Project Team. Evaluation of the counterweight
programme for obesity management in primary care: a starting
point for continuous improvement. Br J Gen Pract. 2008;58:
548–54.
24. Elliott RA, Ross-Degnan D, Adams AS, Safran DG, Soumerai
SB. Strategies for coping in a complex world: adherence among
older adults with chronic illness. J Gen Intern Med. 2007;22:
805–10.
25. Grant RW, Devita NG, Singer DE, Meigs JB. Polypharmacy and
medication adherence in patients with type 2 diabetes. Diabetes
Care. 2003;26:1408–12.
26. Volpe M, Chin D, Paneni F. The challenge of polypharmacy in
cardiovascular medicine. Fundam Clin Pharmacol. 2010;24:9–17.
27. Benner JS, Chapman RH, Petrilla AA, Tang SS, Rosenberg N,
Schwartz JS. Association between prescription burden and
medication adherence in patients initiating antihypertensive and
lipid-lowering therapy. Am J Health Syst Pharm. 2009;66:
1471–7.
28. Harder S, Saal K, Blauth E, Beyer M, Gerlach FM. Appropri-
ateness and surveillance of medication in a cohort of diabetic
patients on polypharmacy. Int J Clin Pharmacol Ther. 2009;47:
104–10.
29. Linne ´ Y, Rooth P, Ro ¨ssner S. Success rate of orlistat in primary-
care practice is limited by failure to follow prescribing recom-
mendations: the referral letter content vs. clinical reality. Int J
Obes Relat Metab Disord. 2003;27:1434–5.
758 Pharm World Sci (2010) 32:752–758
123